Close Menu

NEW YORK – Interpace Diagnostics said after the close of the market on Wednesday that its third quarter revenues increased 33 percent year over year.

The Parsippany, New Jersey-based firm also announced that it has changed its name to Interpace Biosciences to better reflect its new business model combining esoteric molecular diagnostic testing with the new drug discovery and development services business it acquired from Cancer Genetics in July.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.